Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorTessier Cloutier, B
Clarke, A E
Hansen, J E
Urowitz, M B
Fortin, P R
Wallace, D J
Ginzler, E M
Dooley, M A
Senécal, J L
Peschken, C A
Bae, S C
Hanly, J G
Criswell, L A
Barr, S G
Publication Begin page117
Publication End page21
MetadataShow full item record
AbstractEvidence points to a decreased breast cancer risk in systemic lupus erythematosus (SLE). We analyzed data from a large multisite SLE cohort, linked to cancer registries.
Information on age, SLE duration, cancer date, and histology was available. We analyzed information on histological type and performed multivariate logistic regression analyses of histological types according to age, SLE duration, and calendar year.
We studied 180 breast cancers in the SLE cohort. Of the 155 cases with histology information, 11 were referred to simply as 'carcinoma not otherwise specified'. In the remaining 144 breast cancers, the most common histological type was ductal carcinoma (n = 95; 66%) followed by lobular adenocarcinoma (n = 11; 8%), 15 cancers were of mixed histology, and the remaining ones were special types. In our regression analyses, the independent risk factors for lobular versus ductal carcinoma was age [odds ratio (OR) 1.07, 95% confidence interval (CI) 1.01-1.14] and for the 'special' subtypes it was age (OR 1.06, 95% CI 1.01-1.10) and SLE duration (OR 1.05, 95% CI 1.00-1.11).
Generally, up to 80% of breast cancers are ductal carcinomas. Though our results are not definitive, in the breast cancers that occur in SLE, there may be a slight decrease in the ductal histological type. In our analyses, age and SLE duration were independent predictors of histological status.
CitationTessier Cloutier B, Clarke AE, Ramsey-Goldman R, Wang Y, Foulkes W, Gordon C, Hansen JE, Yelin E, Urowitz MB, Gladman D, Fortin PR, Wallace DJ, Petri M, Manzi S, Ginzler EM, Labrecque J, Edworthy S, Dooley MA, Senécal JL, Peschken CA, Bae SC, Isenberg D, Rahman A, Ruiz-Irastorza G, Hanly JG, Jacobsen S, Nived O, Witte T, Criswell LA, Barr SG, Dreyer L, Sturfelt G, Bernatsky S. Breast cancer in systemic lupus erythematosus. Oncology. 2013;85(2):117-21. doi: 10.1159/000353138. Epub 2013 Jul 25. PMID: 23887245; PMCID: PMC3934367.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Copyright © 2013 S. Karger AG, Basel.
- Risk factors for ductal, lobular, and mixed ductal-lobular breast cancer in a screening population.
- Authors: Phipps AI, Li CI, Kerlikowske K, Barlow WE, Buist DS
- Issue date: 2010 Jun
- Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study.
- Authors: Rosenberg LU, Magnusson C, Lindström E, Wedrén S, Hall P, Dickman PW
- Issue date: 2006
- Risk factors for specific histopathological types of postmenopausal breast cancer in the NIH-AARP Diet and Health Study.
- Authors: Nyante SJ, Dallal CM, Gierach GL, Park Y, Hollenbeck AR, Brinton LA
- Issue date: 2013 Aug 1
- Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas.
- Authors: Li CI, Malone KE, Porter PL, Lawton TJ, Voigt LF, Cushing-Haugen KL, Lin MG, Yuan X, Daling JR
- Issue date: 2008 Jan
- Breast cancer in systemic lupus.
- Authors: Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PR, Ginzler E, Romero-Diaz J, Peschken C, Jacobsen S, Hanly JG, Gordon C, Nived O, Yelin EH, Isenberg D, Rahman A, Bae SC, Joseph L, Witte T, Ruiz-Irastorza G, Aranow C, Kamen D, Sturfeldt G, Foulkes WD, Hansen JE, St Pierre Y, Raymer PC, Tessier-Cloutier B, Clarke AE
- Issue date: 2017 Mar